Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial
Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.
How this was made
The 30-second read
Why it matters
The IRB approval expands the trial to a prestigious site, potentially accelerating data collection and de‑risking the program.
Market read
First‑report of a new trial site approval; may influence CMND stock price in the short term.
What to watch
Regulatory timelines, competition from other AUD treatments, and financing needs.
Background
Clearmind Medicine is developing CMND-100, a non‑hallucinogenic neuroplastogen for alcohol use disorder.
Ticker impact
Yale IRB approval enables patient enrollment for Parts B and C of the Phase I/II CMND-100 trial, a new milestone for the company.
Modest upside if enrollment proceeds as expected; risk if delays occur.
IRB approval is a concrete step forward, but trial outcomes remain uncertain.
Market effects
Positive signal for the biotech sector focused on addiction therapies.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche investors.
Counterpoint
Trial enrollment may face operational challenges, and early-stage data could disappoint, limiting upside.
Key entities
- CompanyClearmind Medicine Inc.
Biotech firm developing CMND-100 for AUD.
- Regulatory BodyYale University IRB
Institutional Review Board granting trial site approval.
